Answers are grounded in this paper and cite their sources.
Purpose: This phase 2 trial aimed to evaluate the efficacy and safety of serplulimab combined with nab-paclitaxel and epirubicin in high-risk, early HR+/HER2- breast cancer NCT06394661 Patients and Methods: This multicenter, single-arm, phase 2 trial was conducted in China at 6 hospitals. Patients were eligible if they were 18 years or older, with early HR+/HER2- breast cancer (T1c N1-3 or T2-4 any N), and Ki-67 ≥20%. Participants received intravenous nab-paclitaxel (260 mg/m2) plus intravenous epirubicin (75 mg/m2) on day 1, and intravenous serplulimab (4.5 mg/kg) on day 3 of the treatment cycle, every 3 weeks for 6 cycles. The primary outcome was the rate of pCR (defined as ypT0/is ypN0), assessed in the full analysis set. Results: 101 participants started trial treatment and were included in the full analysis set. pCR was achieved in 23 patients (22.8%, 95% CI 15.3%-32.4%). RCB 0 or 1 was achieved in 34 patients (33.7%, 95% CI 24.8%-43.8%). The pCR rate was higher in PD-L1-positive (combined positive score (CPS)≥1) tumors (44.4%, 95% CI 30.0%-59.9%) than in PD-L1-negative tumors (5.4%, 95% CI 1.4%-15.8%, P <0.001). During the neoadjuvant phase, 30 (29.7%) patients experienced grade 3 or 4 treatment-related adverse events. No new safety signals were identified and there were no treatment-related deaths. Conclusions: Serplulimab combined with nab-paclitaxel and epirubicin showed anti-tumor activity and manageable safety in patients with HR+/HER2- breast cancer, and the pCR rate was higher in PD-L1-positive tumors. These findings support further evaluation of this regimen in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: